Reinvest is best

Discover FP Carmignac Global Equity Compounders

  • Published
  • Length
    4 minute(s) read

Compound interest has been called the 8th wonder of the world. The good news is that more than interest can be compounded. Profitable companies choosing to reinvest their earnings sustainably for future growth can have an equally powerful long-term effect.
We call them Compounders.

What are they?

Compounders are companies that today show the characteristics we believe are needed to successfully grow over the long-term:

  • Carmignac

    Companies with sound financials, sustainable profitability, low debt and predictable long-term growth prospects.

  • Carmignac
    A long-term focus

    Companies with a long-term vision, reinvesting their earnings to grow the business for the future and to remain profitable over time.

  • Carmignac

    Companies with strong Environmental, Social and Governance (ESG) profiles, making a measurable positive contribution to society and the environment.

The magic of Compounders


Taking advantage of their long-term effect

Discover FP Carmignac Global Equity Compounders, a “buy and hold” investment solution investing in shares of sustainable, high-quality companies across the world. The Fund aims to deliver long-term returns over a recommended investment period of at least five years – but investors can choose to hold it for a lifetime.

Why is this Fund so unique?

Hear from the Fund Managers themselves :

FP Carmignac Global Equity Compounders invests in what we think are the best bets for long-term sustainable growth – the Compounders – and it does so while mitigating the effects of changing economic cycles. In following these long-term goals, the Fund Managers always keep an eye on the road: in addition to a rigorous stock selection, they optimise the portfolio by adjusting the sizing of their positions to cyclical and defensive stocks according to the direction of the cycle.


The Fund seeks to achieve steady capital growth over the long term for UK investors looking to put their capital to good use – and to have a team of investment professionals handling the process for them.

FP Carmignac Global Equity Compounders

Invest sustainably for the long-term, while keeping an eye on the road.


Our Compounders revealed

The result of the strong and rigorous investment process of FP Carmignac Global Equity Compounders is a low-turnover, concentrated portfolio of ~40 high conviction names. Discover some of the high quality, sustainable companies which made it into our portfolio:

  • Microsoft Corporation – A US Technology company

    Founded by Bill Gates and Paul Allen more than 45 years ago, Microsoft has since become a leading reference in the technology industry. With a large offering of products and services, the firm has demonstrated its strong, sustainable business model and ability to grow over time through innovation. For instance, its software Office 365 exhibits a strong value proposition with double-digit growth, benefitting from strong network effects. Microsoft is not only proving its value through numbers, but also through its commitment to empowering people: all stakeholders are considered when strategic decisions are made.

  • Novo Nordisk – A Danish pharmaceutical company

    Novo Nordisk is a pharmaceutical company created almost a century ago, specializing in developing, manufacturing, and marketing biologic hormone products and devices for a range of diseases among which diabetes treatment is dominant. The company has taken advantage of significant growth opportunities through strong research and development pipelines (diabetes, obesity). By the nature of its business, Novo Nordisk has a positive impact on society by helping populations to treat illnesses. But it goes far beyond that: it also developed several initiatives to contribute positively to society (affordability and access programmes for low- and middle-income countries, prevention of chronic diseases) and the environment (zero environmental impact target).

  • Zoetis – A US animal medicine and vaccine company

    Founded in 1952, and based in Kalamazoo (Michigan), Zoetis is the largest ‘pure play’ animal health company in the world with a global share of 18% in a USD 22 billion market focusing on livestock and companion animals. The firm is undoubtedly a leader in the industry, benefitting from both the rising global demand for animal health products and the loyalty of its key customers (livestock producers, veterinarians), demonstrating the power of its business model. And that is not where it ends: Zoetis seeks to create value for society, striving to ensure a safe and sustainable food supply, putting a strong emphasis on the wellness of its employees and wider stakeholders and promoting the veterinary profession.

Source: Companies’ websites, Bloomberg, 2021.

FP Carmignac Global Equity Compounders

A global, high-conviction equity fund for long-term investors

Discover the fund

Key points:

    • A fund focusing on high quality companies with sustainable profitability, “compounders” that reinvest their earnings for future growth.

    • A concentrated, low turnover portfolio of high-conviction names seeking to achieve steady capital growth over the long term.

    • An investment process based on rigorous fundamental analysis, quantitative screening, and a socially responsible investment approach.

Fund managers:

  • Mark Denham
    Fund Manager
    Head of European Equities

    Mark Denham is a Fund Manager and Head of European Equities. Mark joined Carmignac in June 2016, from Aviva Investors where he was a Fund Manager and Head of Pan-European Equities. Prior to joining Aviva Investors in 2003, Mark occupied roles of Director of European Equities at Insight Investment and Fund Manager at National Mutual Life. He graduated from Cambridge University with a degree in Natural Sciences and holds a Postgraduate Certificate in Advanced Mathematics.

  • Obe Ejikeme
    Fund Manager

    Obe Ejikeme is a Fund Manager within the Cross Asset team. Obe joined Carmignac in 2014 as Quantitative Equity Analyst . He started his career in 2003 at FactSet Research Systems as a Senior Consultant. Then, he worked for seven years at Bank of America Merrill Lynch where he was Head of European Equity and Quantitative Strategy. Obe holds a Bachelor in Computer Science from the University of Hull.

FP Carmignac Global Equity Compounders A GBP ACC


Recommended minimum investment horizon

Lower risk Higher risk

Potentially lower return Potentially higher return

1 2 3 4 5 6 7
Main risks of the Fund

EQUITY: The Fund may be affected by stock price variations, the scale of which is dependent on external factors, stock trading volumes or market capitalization.

CURRENCY: Currency risk is linked to exposure to a currency other than the Fund’s valuation currency, either through direct investment or the use of forward financial instruments.

DISCRETIONARY MANAGEMENT: Anticipations of financial market changes made by the Management Company have a direct effect on the Fund's performance, which depends on the stocks selected.

The Fund presents a risk of loss of capital.

FP Carmignac Global Equity Compounders A GBP ACC

2019 2020 2021 2022 2023 2024 (YTD)
Year to date
FP Carmignac Global Equity Compounders A GBP ACC - +23.05 % +22.62 % -19.02 % +20.98 % +11.83 %
Reference Indicator - +19.85 % +22.94 % -7.83 % +16.81 % +6.73 %

Scroll right to see full table

3 Years 5 Years 10 Years
FP Carmignac Global Equity Compounders A GBP ACC +8.32 % - -
Reference Indicator +9.22 % - -

Scroll right to see full table

Source: Carmignac at 30/04/2024

Maximum subscription fees paid to distributors : 0,00%
Redemption Fees : 0,00%
Ongoing Charges : 0.90%
Conversion Fee : -
Management Fees : 0,82%
Performance Fees : 0,00%